2014

Scioderm initiates phase IIb study of Epidermolysis Bullosa

Tuesday, January 7, 2014

Scioderm, a privately-held, clinical-stage pharmaceutical company, has initiated a phase IIb study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a rare, genetic connective tissue disorder that typically manifests at birth or early childhood.

[Read More]

Amgen, UCB release positive phase II data for romosozumab

Tuesday, January 7, 2014

Amgen and UCB have announced results from a phase II trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck. Significant increases also were observed in the first BMD assessment at three months. Moreover, in exploratory analyses, increases observed at the lumbar spine and hip were significantly greater than those observed with current treatments FOSAMAX (alendronate sodium) and FORTEO/FORSTEO (teriparatide).

[Read More]

MIMETAS appoints Todd Chappell general manager, U.S. Affairs

Tuesday, January 7, 2014

BioHealth Innovation (BHI) and MIMETAS, a developer of organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models, have announced Todd Chappell, MBA, an entrepreneur-in-residence for BHI, has been named general manager, U.S. Affairs for MIMETAS. A Netherlands-based company, MIMETAS is establishing its offices within BHI’s headquarters in Rockville, Md. MIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.

[Read More]

Six academic institutions to share $540 million cancer research gift

Tuesday, January 7, 2014

Memorial Sloan-Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig. The gift is among the largest publicly recorded gifts to cancer research made by a private organization, bringing the total funding to date for Ludwig Centers and endowed professorships at the six institutions to $900 million. The total new gift received by Memorial Sloan-Kettering is $90 million. Ludwig’s global contribution to advancing cancer research now reaches $2.5 billion.

[Read More]

Soligenix appoints Richard Straube chief medical officer

Tuesday, January 7, 2014

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, has appointed Richard Straube, M.D., as its senior vice president and chief medical officer.

[Read More]